Oxford Immunotec Global (OXFD) Stock Price, News & Analysis

Company Overview

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States, Europe, Asia, and internationally. The company develops its products using its T-SPOT technology platform that measures marker-specific cellular (T cells) responses at a single cell level and inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis; and reagents and methods to purify white blood cells for use in immunology assays. In addition, the company offers T-SPOT.CMV, an immune monitoring test for cytomegalovirus (CMV) for the quantification of effector T cells that respond to stimulation by antigens specific for CMV, as well as for the monitoring of CMV-seropositive responses in transplant recipients at various time-points post-transplantation applications. It serves independent laboratories, hospital systems, and public and private institutions. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.

Key Stats

• Today's Range: $21.99 to $21.99
• 50-Day Range: $21.88 to $21.99
• 52-Week Range: $8.37 to $23.11
• Volume: N/A
• Average Volume: 1.10 million shs
• Market Capitalization: $570.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OXFD Stock Analysis - Frequently Asked Questions

How were Oxford Immunotec Global's earnings last quarter?

Oxford Immunotec Global PLC (NASDAQ:OXFD) posted its quarterly earnings results on Tuesday, November, 3rd. The company reported ($0.01) EPS for the quarter, hitting analysts' consensus estimates of ($0.01). The firm earned $19.44 million during the quarter, compared to analyst estimates of $18.58 million. Oxford Immunotec Global had a negative trailing twelve-month return on equity of 8.39% and a negative net margin of 30.51%.

What other stocks do shareholders of Oxford Immunotec Global own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oxford Immunotec Global investors own include Intel (INTC), Gilead Sciences (GILD), AbbVie (ABBV), Bristol Myers Squibb (BMY), Dynavax Technologies (DVAX), Enterprise Products Partners (EPD) and Gold Resource (GORO).

Company Calendar

• Last Earnings: 11/03/2020
• Today: 6/18/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic Substances
• Sub-Industry: N/A
• Current Symbol: NASDAQ:OXFD
• CIK: 1586049
• Web: www.oxfordimmunotec.com
• Phone: 44-0-12-3544-2780
• Fax: N/A
• Employees: 273
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.81 million
• Net Margins: -30.51%
• Pretax Margin: N/A
• Return on Equity: -8.39%
• Return on Assets: -7.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.96
• Quick Ratio: 14.85

Sales & Book Value

• Annual Sales: $73.71 million
• Price / Sales: 7.75
• Cash Flow: $0.02 per share
• Price / Cash Flow: 1,408.78
• Book Value: $8.08 per share
• Price / Book: 2.72

Miscellaneous

• Outstanding Shares: 25,962,000
• Free Float: N/A
• Market Cap: $570.90 million
• Optionable: Not Optionable
• Beta: 1.42